All In Biotech

Drug Trial Radar · NCT01108783

A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Desloratadine 5 mg for the Treatment of Seasonal Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

720

Actual

Start

Apr 2003

Primary completion

Aug 2003

Study completion Feb 2004

Sponsor

Lead sponsor
Faes Farma, S.A.Industry
Sponsor type
Industry
First posted
Apr 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • BilastineDrug

    20 mg (encapsulated) tablets QD/14 days

  • DesloratadineDrug

    5 mg (encapsulated) tablets QD/14 days

  • PlaceboDrug

    (encapsulated) Tablets QD/14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC of TSSTime frame: 14 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.